The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
03
2020
accepted:
30
06
2020
revised:
21
05
2020
pubmed:
10
7
2020
medline:
18
9
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) are commonly prescribed medications that have been shown to have contradicting effects on cancer. We aimed to investigate the effect of pantoprazole and other PPIs on prostate cancer (PCa) specific mortality (PCSM), use of androgen deprivation therapy (ADT), and PCa diagnosis using a large Canadian population-based cohort. We identified 21,512 men aged ≥ 66, with a history of a single negative prostate biopsy and no previous use of any of the analyzed medications between 1994 and 2016. Multivariable Cox regression models with time-dependent covariates were used to assess the associations of PPIs with PCa outcomes. All models included other medications with a putative chemopreventative effect on PCa-outcomes, and were adjusted for age, rurality, comorbidity, and study inclusion year. Over a mean follow-up of 8.06 years (SD 5.44 years), 10,999 patients (51.1%) used a PPI, 5187 patients (24.1%) had PCa, 2043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. For every 6 months of cumulative use, pantoprazole was associated with a 3.0% (95% CI 0.3-6.0%) increased rate of ADT use, while any use of other PPIs was associated with a 39.0% (95% CI 18.0-64.0%) increased risk of PCSM. No association was found with PCa diagnosis. Upon validation of the potentially negative association of PPIs with PCa, PPI use may need to be reassessed in PCa patients.
Sections du résumé
BACKGROUND
Proton pump inhibitors (PPIs) are commonly prescribed medications that have been shown to have contradicting effects on cancer. We aimed to investigate the effect of pantoprazole and other PPIs on prostate cancer (PCa) specific mortality (PCSM), use of androgen deprivation therapy (ADT), and PCa diagnosis using a large Canadian population-based cohort.
METHODS
We identified 21,512 men aged ≥ 66, with a history of a single negative prostate biopsy and no previous use of any of the analyzed medications between 1994 and 2016. Multivariable Cox regression models with time-dependent covariates were used to assess the associations of PPIs with PCa outcomes. All models included other medications with a putative chemopreventative effect on PCa-outcomes, and were adjusted for age, rurality, comorbidity, and study inclusion year.
RESULTS
Over a mean follow-up of 8.06 years (SD 5.44 years), 10,999 patients (51.1%) used a PPI, 5187 patients (24.1%) had PCa, 2043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. For every 6 months of cumulative use, pantoprazole was associated with a 3.0% (95% CI 0.3-6.0%) increased rate of ADT use, while any use of other PPIs was associated with a 39.0% (95% CI 18.0-64.0%) increased risk of PCSM. No association was found with PCa diagnosis.
CONCLUSIONS
Upon validation of the potentially negative association of PPIs with PCa, PPI use may need to be reassessed in PCa patients.
Identifiants
pubmed: 32641738
doi: 10.1038/s41391-020-0248-9
pii: 10.1038/s41391-020-0248-9
doi:
Substances chimiques
Androgen Antagonists
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-629Références
CCSsACoCS. Canadian Cancer Statistics 2018. 2018. http://www.cancer.ca/Canadian-Cancer-Statistics-2018-EN .
CoAC S. Key Statistics for Prostate Cancer. 2019. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html .
Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, et al. Association of treatment with 5alpha-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179:812–9.
doi: 10.1001/jamainternmed.2019.0280
Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013;105:1123–31.
doi: 10.1093/jnci/djt170
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl J Med. 2012;367:1792–802.
doi: 10.1056/NEJMoa1201735
Gesmundo I, Di Blasio L, Banfi D, Villanova T, Fanciulli A, Favaro E, et al. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3beta signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett. 2019;449:252–62.
doi: 10.1016/j.canlet.2019.02.028
Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–9.
doi: 10.1016/S0016-5085(00)70135-1
Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.
doi: 10.1136/bmjopen-2017-017739
Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172–7.
doi: 10.1016/j.canep.2018.02.004
Tran KT, McMenamin UC, Proton pump inhibitor histamine-2 receptor antagon use risk liver cancer two population-based studies. 2018;48:55–64.
Halfdanarson OO, Fall K, Ogmundsdottir MH, Lund SH, Steingrimsson E, Ogmundsdottir HM, et al. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study. Pharmacoepidemiology drug Saf. 2019;28:471–8.
doi: 10.1002/pds.4702
Canitano A, Iessi E, Spugnini EP, Federici C, Fais S. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett. 2016;376:278–83.
doi: 10.1016/j.canlet.2016.04.015
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28–35.
doi: 10.1136/gutjnl-2017-314605
Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.
doi: 10.1136/bmj.l1580
Soriano LC, Soriano-Gabarró M, García Rodríguez LA. Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network. BMC Cancer. 2018;18:402.
doi: 10.1186/s12885-018-4265-1
Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol. 2017;46:80–4.
doi: 10.1016/j.canep.2016.12.006
Cao Y, Chen M, Tang D, Yan H, Ding X, Zhou F, et al. The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses. Cell Death Dis. 2018;9:604.
doi: 10.1038/s41419-018-0642-6
Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J cancer. 2015;112:832–40.
doi: 10.1038/bjc.2015.17
Hansen AR, Tannock IF, Templeton A, Chen E, Evans A, Knox J, et al. Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Oncologist. 2019;24:1188–94.
doi: 10.1634/theoncologist.2018-0621
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.
doi: 10.7326/0003-4819-147-8-200710160-00010
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12:e1001885.
doi: 10.1371/journal.pmed.1001885
Institute of Clinical Evaluative Sciences Homepage. 2019. http://www.ices.on.ca .
The Johns Hopkins ACG (R) System version 10.0.
Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, et al. Population-based outcomes of men with a single negative prostate biopsy: importance of continued follow-up among older patients. Urologic Oncol. 2019;37:298.e19–.e27.
doi: 10.1016/j.urolonc.2019.01.030
The Top 300 of 2019. 2019. www.clincalc.com .
Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697–710.
doi: 10.1038/nrgastro.2017.117
Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017;153:35–48.
doi: 10.1053/j.gastro.2017.04.047
Hayashi H, Taniai E, Morita R, Hayashi M, Nakamura D, Wakita A, et al. Enhanced liver tumor promotion but not liver initiation activity in rats subjected to combined administration of omeprazole and beta-naphthoflavone. J toxicological Sci. 2012;37:969–85.
doi: 10.2131/jts.37.969
Huang L, Qi DJ, He W, Xu AM. Omeprazole promotes carcinogenesis of fore-stomach in mice with co-stimulation of nitrosamine. Oncotarget. 2017;8:70332–44.
doi: 10.18632/oncotarget.19696
Peng YC, Lin CL, Hsu WY, Lu IT, Yeh HZ, Chang CS, et al. Proton Pump inhibitor use is associated with risk of pancreatic cancer: a nested case-control study. Dose Response. 2018;16:1559325818803283.
doi: 10.1177/1559325818803283
Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: a Korean nationwide prospective cohort study. PloS ONE. 2017;12:e0189114.
doi: 10.1371/journal.pone.0189114
Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, et al. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:431–7.
doi: 10.1038/s41391-018-0046-9
Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol: Off J Eur Soc Med Oncol. 2017;28:2658–69.
doi: 10.1093/annonc/mdx348
Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14:273–87.
doi: 10.1038/nrmicro.2016.17
Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539–48.
doi: 10.1038/s41391-018-0061-x
Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:345–54.
doi: 10.1038/s41391-018-0041-1
Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199:161–71.
doi: 10.1016/j.juro.2017.08.001
Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351–8.
doi: 10.1080/19490976.2017.1284732
Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16:961–8.
doi: 10.1002/pds.1454